In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma.
Therapy of disseminated neuroblastoma remains an unsolved problem in pediatric oncology. Therefore, new therapeutic approaches have to be developed for this malignancy. In this paper, we investigated the possibility of the in vitro generation and expansion of lymphokine-activated killer (LAK) cells in patients with disseminated neuroblastoma. Although the patients had very low Natural Killer (NK) activity, it was possible to induce LAK activity in peripheral mononuclear lymphocytes (PMNC) by incubation with Interleukin-2 (IL-2). Moreover, the PMNCs could be expanded up to 50-fold in the presence of Interleukin-2 while maintaining or even increasing their LAK activity. The target cells were neuroblastoma cell lines and, in one case, autologous neuroblastoma cells. Additionally, it was possible to induce LAK cell activity against autologous neuroblastoma cells in bone marrow-derived mononuclear cells.
Handgretinger
R
R
Children's University Hospital, Department Hematology/Oncology, Tuebingen, FRG.
Bruchelt
G
G
Kimmig
A
A
Dopfer
R
R
Niethammer
D
D
Treuner
J
J
D001853:Bone Marrow / Q000502:physiology; D002648:Child; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000502:physiology*; D007937:Leukapheresis; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000097:blood* / Q000473:pathology / Q000628:therapy; D014407:Tumor Cells, Cultured
D007376:Interleukin-2